D.C. Lung Cancer Conference 2024
October 19, 2024
Agenda

7:30 a.m.
Registration, Breakfast, and Visit the Exhibitors

8:00 a.m.
Welcome Remarks
Stephen V. Liu, MD

Session I: Diagnosis
Moderator: Joshua E. Reuss, MD

8:05 a.m.
The Value of Research: A Patient Perspective
Terri Conneran, MD

8:15 a.m.
Lung Cancer Screening
Eric D. Anderson, MD

8:25 a.m.
Modern Bronchoscopy Techniques
Rebecca Krochmal, MD

8:35 a.m.
The Value of Biomarker Testing
Christine Lovly, MD

8:45 a.m.
Liquid Biopsy: Now and the Future
Charu Aggarwal, MD
8:55 a.m.
Artificial Intelligence: Actual Impact?
Sandip Patel, MD

9:05 a.m.
Panel Discussion
Moderator: Joshua E. Reuss, MD
Panelists: C. Aggarwal, E. Anderson, T. Conneran, R. Krochmal, C. Lovly, S. Patel

9:20 a.m.
Coffee Break and Visit the Exhibits

**Session II: Early Stage Non-Small Cell Lung Cancer (NSCLC)**
**Moderator: Stephen Broderick, MD**

9:35 a.m.
Extent of Resection: Is Less More?
Marc Margolis, MD

9:45 a.m.
SBRT for Early Stage NSCLC
TBD

9:55 a.m.
Targeted Therapy for Resected NSCLC
Narjust Florez, MD

10:05 a.m.
Adjuvant Immunotherapy: Who Benefits?
Ryan D. Gentzler, MD

10:15 a.m.
Neoadjuvant and Perioperative Immunotherapy
Tina Cascone, MD, PhD
10:25 a.m.  
Effect of Immunotherapy on Surgery  
Jonathan Spicer, MD

10:35 a.m.  
Treating Unresectable Stage III NSCLC  
Nagla F. Abdel Karim, MD

10:45 a.m.  
Panel Discussion  
Moderator: Stephen Broderick, MD  

11:00 a.m.  
Debate Introduction

11:05 a.m.  
Pathologic Complete Response (pCR) after Neoadjuvant: NO to More Therapy  
Joshua E. Reuss, MD

11:15 a.m.  
pCR after Neoadjuvant: YES to More Therapy  
Marina Chiara Garassino, MBBS

11:25 a.m.  
Lunch and Visit the Exhibits

11:55 a.m.  
Sponsored Symposium

12:40 p.m.  
Dessert and Visit the Exhibits
Session III: Immunotherapy and Advanced Thoracic Cancers
Moderator: Faysal Haroun, MD

1:10 p.m.
Emerging Systemic Strategies for Mesothelioma
Ibiayi Dagogo Jack, MD

1:20 p.m.
TTFields for Mesothelioma and NSCLC
Ticiana Leal, MD

1:30 p.m.
Small Cell Lung Cancer (SCLC): Current Standards and Emerging Agents
Taofeek Owonikoko, MD

1:40 p.m.
Dual Checkpoint for NSCLC: What’s the CTLA4-11
Hossein Borghaei, DO, MS

1:50 p.m.
Optimal Duration of Immunotherapy for NSCLC
Balazs Halmos, MD

2:00 p.m.
Immunotherapy Toxicity for Daily Practice
Laura Macke, MS, FNP-C, AOCNP

2:10 p.m.
Surgery and Stage IV NSCLC: When, Why, and for Whom?
Brendon Stiles, MD

2:20 p.m.
Panel Discussion
Moderator: Faysal Haroun, MD
Panelists: H. Borghaei, B. Halmos, I. Jack, T. Leal, L. Macke, T. Owonikoko, B. Stiles
2:35 p.m.
Coffee Break and Visit the Exhibits

**Session IV: Targeted Therapy for Advanced NSCLC**
**Moderator: Chul Kim, MD**

2:45 p.m.
Trop2 and MET ADCs
Benjamin Levy, MD

2:55 p.m.
RET: Past, Present, Future
Alex Drilon, MD

3:05 p.m.
First Line Options for ALK/ROS1 NSCLC
Susan C. Scott, MD, MA

3:15 p.m.
Overcoming Resistance in ALK/ROS1 NSCLC
Jessica Lin, MD

3:25 p.m.
Strategies for KRAS Mutant NSCLC
Alex Spira, MD

3:35 p.m.
Panel Discussion
Moderator: Chul Kim, MD
Panelists: A. Drilon, B. Levy, J. Lin, S. Scott, A. Spira

3:45 p.m.
Coffee and Visit the Exhibits
Session V: Targeted Therapy for Advanced NSCLC #2
Moderator: Brinda Gupta, MD

3:55 p.m.
First-Line EGFR: Which Option is Best?
Zosia Piotrowska, MD, MHS

4:05 p.m.
Exon 20 (HER2 and EGFR): Evolving Options
Chul Kim, MD

4:15 p.m.
What’s Next for EGFR?
Helena Yu, MD

4:25 p.m.
NTRK and NRG1: Needles in the Haystack
Amin Benyounes, MD

4:35 p.m.
Managing BRAF and METex14 Mutant NSCLC
Irina Veytsman, MD

4:45 p.m.
Panel Discussion
Moderator: Brinda Gupta, MD
Panelists: A. Benyounes, C. Kim, Z. Piotrowska, I. Veytsman, H. Yu

4:55 p.m.
Closing Remarks
Stephen V. Liu, MD

5:00 p.m.
Adjourn